nach oben

Digestive Diseases and Sciences

Erschienen in:

01.02.2009 | Original Article

Endocan Expression Correlated with Poor Survival in Human Hepatocellular Carcinoma

verfasst von: Geng-Wen Huang, Yi-Ming Tao, Xiang Ding

Erschienen in: Digestive Diseases and Sciences | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Hepatocellular carcinoma (HCC) is the second leading cause of cancer death in China. We aimed to first present the expression of endocan in HCC tissue and its correlation with the clinicopathological features and overall survival of patients with HCC after curative hepatectomy. Immunohistochemical detection of endocan, CD34, and vascular endothelial growth factor (VEGF) were performed on samples from 100 patients with HCC. Endocan protein was expressed in endothelium of HCC tissue in all specimens, but was not expressed in endothelium of pericarcinomatous liver tissue and normal liver tissue. Microvessel density (MVD) denoted by endocan (endocan-MVD) in HCC was correlated with microscopic venous invasion and VEGF expression (P < 0.05). Survival analysis showed that overall survival of patients was inversely associated with endocan-MVD (P < 0.01). Multivariate analysis showed that endocan-MVD was an independent prognostic marker for overall survival of HCC (P < 0.01). In conclusion, endocan-MVD was a significant factor to predict the prognosis of HCC patients after curative hepatectomy.

He J, Gu D, Wu X, Reynolds K, Duan X, Yao C et al (2005) Major causes of death among men and women in China. N Engl J Med 353:1124–1134. doi:10.1056/NEJMsa050467 PubMedCrossRef

Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C et al (1999) Hepatectomy for hepatocellular carcinoma: toward zero hospital death. Ann Surg 229:322–330. doi:10.1097/00000658-199903000-00004 PubMedCrossRef

Hubert C, Sempoux C, Rahier J, Horsmans Y, Geubel A, Van Beers BE et al (2007) Prognostic risk factors of survival after resection of hepatocellular carcinoma. Hepatogastroenterology 54(78):1791–1797PubMed

Ibrahim S, Roychowdhury A, Hean TK (2007) Risk factors for intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. Am J Surg 194:17–22. doi:10.1016/j.amjsurg.2006.06.051 PubMedCrossRef

Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP (2007) Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer 43:979–992. doi:10.1016/j.ejca.2007.01.004 PubMedCrossRef

Wang SM, Ooi LL, Hui KM (2007) Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma. Clin Cancer Res 13:6275–6283. doi:10.1158/1078-0432.CCR-06-2236 PubMedCrossRef

Poon RTP, Fan ST, Wong J (2000) Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 232:10–24. doi:10.1097/00000658-200007000-00003 CrossRef

Wang W, Yang LY, Huang GW, Lu WQ, Yang ZL, Yang JQ et al (2004) Genomic analysis reveals RhoC as a potential marker in hepatocellular carcinoma with poor prognosis. Br J Cancer 90:2349–2355PubMed

Sun B, Zhang S, Zhang D, Du J, Guo H, Zhao X et al (2006) Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncol Rep 16:693–698PubMed

10.

Tanaka S, Arii S (2006) Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma. Int J Clin Oncol 11:82–89. doi:10.1007/s10147-006-0566-5 PubMedCrossRef

11.

Huang GW, Yang LY, Lu WQ (2005) Expression of hypoxia-inducible factor 1 a and vascular endothelial growth factor in hepatocellular carcinoma: impact on neovascularization and survival. World J Gastroenterol 11:1705–1708PubMed

12.

Claudio PP, Russo G, Kumar CACY et al (2004) pRb2/p130, Vascular Endothelial Growth Factor, p27(KIP1), and proliferating cell nuclear antigen expression in hepatocellular carcinoma. Clin Cancer Res 10:3509–3517. doi:10.1158/1078-0432.CCR-03-0662 PubMedCrossRef

13.

Ikeguchi M, Ueta T, Yamane Y, Hirooka Y, Kaibara N (2002) Inducible nitric oxide synthase and survivin messenger RNA expression in hepatocellular carcinoma. Clin Cancer Res 8:3131–3136PubMed

14.

Poon RT, Ng IO, Lau C et al (2001) Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am J Surg 182:298–304. doi:10.1016/S0002-9610(01)00708-5 PubMedCrossRef

15.

Poon RT, Ng IO, Lau C et al (2002) Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 20:1775–1785. doi:10.1200/JCO.2002.07.089 PubMedCrossRef

16.

Wang SN, Chuang SC, Yeh YT et al (2006) Potential prognostic value of leptin receptor in hepatocellular carcinoma. J Clin Pathol 59:1267–1271. doi:10.1136/jcp.2005.033464 PubMedCrossRef

17.

Yang LY, Lu WQ, Huang GW, Wang W (2006) Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma. BMC Cancer 6:110. doi:10.1186/1471-2407-6-110

18.

Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, Lortat-Jacob H, Bechard D, Lassalle P, Delehedde M (2006) Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochem Biophys Acta 1765:25–37PubMed

19.

van ‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536. doi:10.1038/415530a PubMedCrossRef

20.

Amatschek S, Koenig U, Auer H, Steinlein P, Pacher M, Gruenfelder A et al (2004) Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res 64:844–856. doi:10.1158/0008-5472.CAN-03-2361 PubMedCrossRef

21.

Borczuk AC, Shah L, Pearson GD, Walter KL, Wang L, Austin JH et al (2004) Molecular signatures in biopsy specimens of lung cancer. Am J Respir Crit Care Med 170:167–174. doi:10.1164/rccm.200401-066OC PubMedCrossRef

22.

Grigoriu BD, Depontieu F, Scherpereel A, Gourcerol D, Devos P, Ouatas T et al (2006) Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res 12:4575–4582. doi:10.1158/1078-0432.CCR-06-0185 PubMedCrossRef

23.

Huang GW, Yang LY (2002) Metallothionein expression in hepatocellular carcinoma and its clinical significance. World J Gastroenterol 8:650–653PubMed

24.

Weidner N (1995) Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 36:169–180. doi:10.1007/BF00666038 PubMedCrossRef

25.

El-Assal ON, Yamanoi A, Soda Y, Yamaguchi M, Iqarashi M, Yamamoto A et al (1998) Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 27:1554–1562. doi:10.1002/hep. 510270613 PubMedCrossRef

26.

McDonald DM, Foss AJE (2000) Endothelial cells of tumor vessels: abnormal but not absent. Cancer Metastasis Rev 19:109–120. doi:10.1023/A:1026529222845 PubMedCrossRef

27.

Abid MR, Yi X, Yano K, Shih SC, Aird WC (2006) Vascular endocan is preferentially expressed in tumor endothelium. Microvasc Res 72:136–145. doi:10.1016/j.mvr.2006.05.010 PubMedCrossRef

28.

Tozer GM, Kanthou C, Baguley BC (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5:423–435. doi:10.1038/nrc1628 PubMedCrossRef

29.

Rennel E, Mellberg S, Dimberg A, Petersson L, Botling J, Ameur A et al (2007) Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer. Exp Cell Res 313:1285–1294. doi:10.1016/j.yexcr.2007.01.021 PubMedCrossRef

Titel: Endocan Expression Correlated with Poor Survival in Human Hepatocellular Carcinoma
verfasst von: Geng-Wen Huang
Yi-Ming Tao
Xiang Ding
Publikationsdatum: 01.02.2009
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 2/2009
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-008-0346-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Endocan Expression Correlated with Poor Survival in Human Hepatocellular Carcinoma

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2009

MCM2 and MCM5 as Prognostic Markers in Colon Cancer: A Worthwhile Approach

Antibacterial Action of Selenium-Enriched Probiotics Against Pathogenic Escherichia coli

Paralytic Ileus and Liver Failure—An Unusual Presentation of Advanced Erythropoietic Protoporphyria

Gastrointestinal Manifestations of Behçet’s Disease

Ginkgo biloba (EGb 761) Extract: Effects on the Myenteric Plexus of the Large Intestine in Wistar Rats

The Prevalence of Celiac Disease in Blood Donors in Iceland

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin